Piramal Pharma approves grant of 56.3 lakh stock options
NiveshIQ
NSE: PPLPHARMA · Pharma
Piramal Pharma Ltd.
₹195.68▲ ₹2.25 (+1.16%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on PPLPHARMA. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Piramal Pharma Ltd.
Piramal Pharma Limited (PPLPHARMA) is a pharmaceutical company operating in the United States, Europe, Japan, India, and internationally. The company offers a diverse portfolio of pharmaceutical products and services through its global development and manufacturing facilities and distribution network. Its contract development and manufacturing organization provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products. Piramal Pharma has reported strong quarterly turnaround with robust revenue and margin gains, driven by exceptional volume surge and strong price rally. The company's revenue stood at ₹8869 Cr, with a net income of ₹-326 Cr. With a 'Buy' rating and a target price of ₹203, Piramal Pharma is expected
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹8,171 Cr +110.60% | ₹9,151 Cr +12.00% | ₹8,869 Cr -3.10% |
| EBITDA Margin | 14.64% | 15.79% | 12.80% |
| Net Profit | ₹17.00 Cr -142.50% | ₹92.00 Cr +441.20% | -454.30% |
| EPS | ₹0.14 | ₹0.69 | ₹2.46 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Piramal Pharma Ltd soars 0.83%, gains for fifth straight session
Piramal Alternatives: ₹110 కోట్ల పెట్టుబడిపై 20%పైగా IRRతో భారీ లాభం!
🔒
+ 3 more stories about Piramal Pharma Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹2,752 Cr, PAT ₹-9 Cr, EPS ₹-0.07, EBITDA margin 18.4%. Growth context: revenue QoQ +28.6%, PAT QoQ -93.5%. Street verdict: miss, revenue surprise -0.2%.
No specific capex or expansion announcements have been filed recently; demand conversion and margin discipline on the co...
Forward consensus estimates for the next FY will be the key financial watchpoint as the current year plays out....
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for PPLPHARMA
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track PPLPHARMA alongside your other holdings
Unlock full PPLPHARMA research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Piramal Pharma Ltd.?
NiveshIQ detects active intelligence signals for Piramal Pharma Ltd. (PPLPHARMA) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Piramal Pharma Ltd.?
Piramal Pharma Ltd. operates in the Pharma sector with a market capitalisation of ₹2,378,975.5L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.